Biofunctionalized liposomes to monitor rheumatoid arthritis regression stimulated by Interleukin-23 neutralization

Even after the revolution of rheumatoid arthritis (RA) treatment with biologic agents, this debilitating disease remains a major clinical problem. The outstanding outcomes of the systemic administration of antibodies (Abs) are narrowed by the risk of serious side effects and limited efficacy due to...

ver descrição completa

Detalhes bibliográficos
Autor principal: Lima, Ana Cláudia Fernandes (author)
Outros Autores: Campos, Cláudia F. (author), Cunha, Cristina (author), Carvalho, Agostinho (author), Reis, R. L. (author), Ferreira, Helena Susana Costa Machado (author), Neves, N. M. (author)
Formato: article
Idioma:eng
Publicado em: 2021
Assuntos:
Anti-IL-23 antibodies
Gold nanoparticles
IL-17A inhibition
Liposomes
Rheumatoid arthritis
17A inhibition
anti&#8208
IL&#8208
23 antibodies
Science & Technology
Texto completo:https://hdl.handle.net/1822/75287
País:Portugal
Oai:oai:repositorium.sdum.uminho.pt:1822/75287

Texto Completo

https://hdl.handle.net/1822/75287

Registos relacionados